>You have Intermune at #2 for Hep C, but curious why you don't list them on your 'long/watching' stock list, along with Vertex and Pharmasset?<
The list on the iHub profile page should not be taken too literally. The available space is too small to list every company I follow, so I made some quasi-arbitrary decisions: VRTX is much further along in HCV than ITMN, and VRUS has programs in all three antiviral areas (HIV, HCV, HBV).
Market Data 
Markets 
AI
